Xbrane Biopharma Ab Stock Book Value Per Share
| XBRANE Stock | SEK 0.21 0.01 4.55% |
Xbrane Biopharma AB fundamentals help investors to digest information that contributes to Xbrane Biopharma's financial success or failures. It also enables traders to predict the movement of Xbrane Stock. The fundamental analysis module provides a way to measure Xbrane Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xbrane Biopharma stock.
Xbrane |
Xbrane Biopharma AB Company Book Value Per Share Analysis
Xbrane Biopharma's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Xbrane Biopharma Book Value Per Share | 12.99 X |
Most of Xbrane Biopharma's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xbrane Biopharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of Xbrane Biopharma AB is about 12.995 times. This is 864.41% lower than that of the Healthcare sector and notably lower than that of the Drug Manufacturers - Specialty & Generic industry. The book value per share for all Sweden stocks is 99.33% higher than that of the company.
Xbrane Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xbrane Biopharma's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Xbrane Biopharma could also be used in its relative valuation, which is a method of valuing Xbrane Biopharma by comparing valuation metrics of similar companies.Xbrane Biopharma is currently under evaluation in book value per share category among related companies.
Xbrane Fundamentals
| Return On Equity | -0.37 | |||
| Return On Asset | -0.13 | |||
| Operating Margin | (4.61) % | |||
| Current Valuation | 2.32 B | |||
| Shares Outstanding | 27.51 M | |||
| Shares Owned By Insiders | 35.23 % | |||
| Shares Owned By Institutions | 22.09 % | |||
| Price To Earning | (10.92) X | |||
| Price To Book | 7.49 X | |||
| Price To Sales | 75.09 X | |||
| Revenue | 11.53 M | |||
| Gross Profit | (18.27 M) | |||
| EBITDA | (172.74 M) | |||
| Net Income | (188.38 M) | |||
| Cash And Equivalents | 44.32 M | |||
| Cash Per Share | 5.34 X | |||
| Total Debt | 36.48 M | |||
| Debt To Equity | 48.90 % | |||
| Current Ratio | 1.45 X | |||
| Book Value Per Share | 12.99 X | |||
| Cash Flow From Operations | (219.61 M) | |||
| Earnings Per Share | (7.13) X | |||
| Target Price | 136.5 | |||
| Number Of Employees | 74 | |||
| Beta | 1.37 | |||
| Market Capitalization | 2.74 B | |||
| Total Asset | 688.43 M | |||
| Retained Earnings | (29 M) | |||
| Working Capital | 64 M | |||
| Current Asset | 77 M | |||
| Current Liabilities | 13 M | |||
| Z Score | 45.0 | |||
| Net Asset | 688.43 M |
About Xbrane Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xbrane Biopharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xbrane Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xbrane Biopharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| CRM | Salesforce | |
| GOOG | Alphabet Inc Class C |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xbrane Biopharma AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Xbrane Stock analysis
When running Xbrane Biopharma's price analysis, check to measure Xbrane Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xbrane Biopharma is operating at the current time. Most of Xbrane Biopharma's value examination focuses on studying past and present price action to predict the probability of Xbrane Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xbrane Biopharma's price. Additionally, you may evaluate how the addition of Xbrane Biopharma to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |